COCHW · Envoy Medical, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company's ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 10, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $207K | $241K | $225K | $316K | $237K | — | |
| $1.01M | $874K | $742K | $789K | $498K | — | |
| -$798K | -$633K | -$517K | -$473K | -$261K | — | |
| — | -262.66% | -229.78% | -149.68% | -110.13% | — | |
| $14.03M | $12.49M | $10.18M | $8.96M | $4.98M | — | |
| $846K | $1.22M | $1.73M | $1.67M | $885K | — | |
| $7.95M | $7.93M | $6.83M | $7.26M | — | — | |
| — | — | — | $7.28M | $2.59M | — | |
| $23.83M | $22.51M | $19.48M | $18.68M | $8.94M | — | |
| -$23.62M | -$22.27M | -$19.26M | -$18.36M | -$8.71M | -$5.2M | |
| — | -9240.66% | -8558.22% | -5809.81% | -3673.42% | — | |
| — | $1.59M | $816K | — | — | — | |
| $9.42M | — | — | — | $6.13M | $37.67K | |
| $220K | -$1.49M | -$1.54M | -$11.56M | -$7.22M | — | |
| — | -$23.76M | -$20.8M | — | $20.74M | -$251.63K | |
| $2.36M | — | — | — | $1.5M | — | |
| -$23.4M | -$23.76M | -$20.8M | -$29.92M | -$15.92M | -$251.63K | |
| — | -9857.26% | -9242.22% | -9468.99% | -6718.57% | — | |
| -$28.46M | -$28.66M | -$27.97M | -$31.27M | -$15.92M | — | |
| -$23.4M | -$23.75M | -$20.8M | -$29.93M | -$15.93M | — | |
| USD/shares | -$0.77 | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
| USD/shares | -$0.77 | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
| shares | — | 23.26M | 18.79M | 12.3M | 10.12M | — |
| shares | — | 23.26M | 18.79M | 12.3M | 10.12M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $4.27M in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2025-12-31 | USD 919,000 | 10-K filed 2026-03-23 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | $241,000 | $225,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | -$22,270,000 | -$19,256,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | -9240.7% | -8558.2% |